You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Addressing the wireless power problem: A low-power hybrid radio for neuroscience experiments
SBC: SPIKE NEURO LLC Topic: 101Project Summary Closed-loop stimulation is key to the study and treatment of neurological disorders. However, largely due to current wireless power demands, stimulation systems are restricted to wired connections, which impact natural behavior, induce motion artifacts, and limit complexity of study design. While a few wireless recording- only systems have been developed, the power demands of these ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Geostatistical Software for Non-Parametric Geostatistical Modeling of Uncertainty
SBC: BIO-ANALYTICS, INC. Topic: NLM7. Project Summary/Abstract A key component in any investigation of association and/or cause-effect relationships between the environment and health outcomes is the availability of accurate and precise models of exposure. Because the cost of collecting field data is often prohibitive, it is critical to incorporate any source of secondary information available to supplement sparse datasets. Seconda ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Intranasal Formulations of Allopregnanolone, a Regenerative Therapeutic for Alzheimer's Disease
SBC: NEUTHERAPEUTICS, LLC Topic: NIAProject Summary/Abstract Alzheimer’s disease (AD) is a progressive multifactorial disease affecting more than 50 million people worldwide and is the most common dementia of late-life. To date, no interventions have demonstrated substantial therapeutic efficacy to prevent, delay or treat AD. Current thinking in the field embraces the complexity of AD pathophysiology, which has enabled a more dive ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
In vivo feasibility of a smart needle ablation treatment for liver cancer
SBC: CURRENT SURGICAL INC Topic: 102Project Summary A significant number (~30-50%) of liver cancers have no curative treatments due to their proximity to critical anatomy. Minimally invasive thermal ablation is a promising treatment for these untreatable solid tumors. If delivered precisely, ablations offer the treatment efficacy of traditional surgery with lower patient risk, clinician time, and overall cost. Existing ablation tech ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Computational Infrastructure for Automated Force Field Development and Optimization
SBC: ATTMOS Inc. Topic: 400Project AbstractOur overarching goal is to provide reliable and efficient tools that can be used in structure based drug discovery (SBDD). One crucial component of SBDD is to predict the structure of a drug molecule that binds to a protein involved in a certain disease. This is usually achieved using computer tools and the process consists of two steps, namely hit identification and lead optimizat ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
New approach for immune modulation against T1D
SBC: EVOQ THERAPEUTICS, INC. Topic: 200PROJECT SUMMARY/ABSTRACT Type 1 diabetes (T1D) is an autoimmune disease that affects 1 in 300 people by the age of 18 in the US. T1D is characterized by acute onset of hyperglycemia resulting from immune-mediated destruction of the insulin- producing β-cells in the pancreas. There is currently no cure for T1D and the disease requires constant management where the current standard of care/manageme ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Optimized Ratiometric Voltage-Sensitive Dyes for Cardiac Research, Safety Pharmacology
SBC: POTENTIOMETRIC PROBES LLC Topic: 400Project Summary/Abstract Potentiometric Probes The overall goal of this Phase II SBIR project is to commercialize tools, invented by the founders of Potentiometric Probe, LLC, for high-fidelity optical recording of electrical activity in cardiac cells, tissues, and whole hearts. Potentiometric Probes develops organic voltage-sensitive dyes (VSDs) that convert the changes in voltage across cell mem ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections.
SBC: TSRL, INC. Topic: NIAIDThe objective of this grant is the preclinical development of MRS-2541, a novel antibiotic structure targeting Gram+ bacteria by a new mechanism of action. MRS-2541 inhibits bacterial methionyl- tRNA synthetase required for bacterial protein synthesis, which is very different from its mammalian counterpart. MRS-2541 is the result of an arduous testing cascade of over 500 compounds requiring broad- ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Fluorescence-Solid Phase Extraction (F-SPE) Platform for Rapid, On-site Detection of PFAS
SBC: Espira, Inc. Topic: NIEHSProject Summary Per-and polyfluoroalkyl substances (PFAS) have become an emerging class of water pollutants that cause serious environmental and health concerns. Due to their wide use in industry, military, and fire protection, PFAS have been spread and present in all kinds of water bodies. Among the over thousand PFAS ever manufactured and used, perfluorooctanesulfonic (PFOS) and perfluorooctanoi ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Engineering next generation supercharged CAR T-cells against solid tumors
SBC: Cellinfinity Bio, Inc. Topic: 102Project summary Adoptive cell therapy has revolutionized cancer treatment and has immense potential to cure a variety of cancer types. Multiple critical barriers exist for current CAR-T therapy particularly in solid tumor, including insufficient T cells trafficking to the cancer site, lack of effective cancer cell killing, severe toxicity, strong immunosuppression in the tumor microenvironment, an ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health